Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
When it comes to experimental cholesterol drugs, all eyes this year are on inclisiran, the $9.7 billion RNAi drug Novartis hopes will replace and vastly outsell Regeneron and Amgen’s PCSK9 inhibitors.
Yet Regeneron has been quietly preparing for approval of its own new cholesterol drug, a niche antibody meant to treat a narrow slice of patients not covered by Praluent, the biotech’s original PCSK9 inhibitor. Last year, the company reported topline, pivotal data. Last week, a BLA submission for the drug, known as evinacumab, was accepted and given priority review by the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
